XML 13 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Net Income (Loss) $ (11,094) $ (9,329)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation 3 4
Non-cash operating lease expense 85 76
Recurring fair value measurements of liabilities (159) 153
Issuance of common stock to vendors 124 0
Loss on disposal of property and equipment 4 0
Stock-based compensation and related charges 575 439
Other 0 (108)
Changes in operating assets and liabilities    
Prepaid and other current assets and other noncurrent assets 542 596
Accounts payable and accrued liabilities 526 (184)
Accrued compensation and benefits (329) 43
Operating lease liabilities (89) (77)
Net cash used in operating activities (9,812) (8,387)
Cash flows from investing activities    
Purchases of property and equipment 0 (4)
Net cash used in investing activities 0 (4)
Cash flows from financing activities    
Payments on insurance financing debt (270) (290)
Proceeds from issuance of common stock and warrants 4,000 9,419
Proceeds from the exercise of warrants 2,503 2,758
Payment of warrant inducement issuance costs (343) 0
Payment of equity issuance costs (456) (567)
Proceeds from issuance of common stock under Employee Stock Purchase Plan 11 0
Shares withheld for payment of employee withholding tax liability (25) 0
Net cash provided by financing activities 5,420 11,320
Net (decrease) increase in cash, cash equivalents and restricted cash (4,392) 2,929
Cash, cash equivalents and restricted cash, beginning of year 12,458 12,409
Cash, cash equivalents and restricted cash, end of period 8,066 15,338
Reconciliation of cash, cash equivalents and restricted cash to the balance sheets    
Cash and cash equivalents 8,040 15,312
Restricted cash 26 26
Total cash, cash equivalents and restricted cash 8,066 15,338
Supplemental disclosures of cash flow information:    
Interest paid 8 10
Supplemental disclosures of non-cash investing and financing activities    
Warrant inducement and equity issuance costs included in accounts payable and accrued liabilities 0 50
Non cash impact of exercise price reset on outstanding warrants related to down round provisions 0 16
Fair value of warrants issued to solicitation agent 94 0
Fair value of warrants issued to placement agent 249 384
Deferred equity issuance costs recognized as a reduction in additional paid-in capital from financing activities 37 0
Insurance financing debt included in prepaid and other current assets and other noncurrent assets 347 461
Incremental fair value of modified warrants (Note 5) $ 1,975 $ 0